Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
enzyme disorders
Biotech
Genentech pays Alector $100M for preclinical Parkinson’s asset
Genentech is committing up to $1.17 billion in milestones and tiered royalties on net sales.
Nick Paul Taylor
Oct 5, 2026 10:09am
BioMarin axes $270M asset after missing phase 3 endpoint
Aug 7, 2026 9:10am
GSK won't pick up Wave's genetic disease RNA editor
Feb 2, 2026 11:14am
Denali ph. 1 Pompe plans hit with clinical hold
Dec 4, 2025 11:52am
BioMarin inks $270M Inozyme buyout, bagging phase 3 prospect
May 16, 2025 8:46am
BioMarin's R&D head hopes pipeline of good ideas won't 'dry out'
Feb 21, 2025 7:00am
